Sign in
Active, not recruitingEarly phase 1

Transformation of Paralysis to Stepping

Key facts

Who runs it
University of Louisville
Where
Louisville, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Early phase 1
People taking part
15 people, planned
Started
30 Sept 2019
Expected to end
31 Dec 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Buspirone
  • Non-invasive Spinal Cord Stimulation
  • Overground stepping
  • Gravity Neutral Device
  • Body Weight Supported Treadmill Training
  • Rolling Walker
Record updated
13 March 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Participants with Motor Complete SCI:; 18-65 years old,; Stable medical condition,; At least 1-year post-injury,; Non-progressive SCI,; Motor complete paraplegia: Unable to voluntarily move any joint of the lower limbs,; Inability to walk independently due to SCI,; Presence of active spinally evoked responses over the lumbo-sacral spinal cord using spinal Cord Transcutaneous Stimulation (scTS)
  • Participants with Motor Incomplete SCI:; 18-65 years old,; Stable medical condition,; At least 1-year post-injury,; Non-progressive SCI,; Motor incomplete paraplegia: Able to voluntarily move at least 1 joint of the lower limbs bilaterally,; Inability to walk independently in the community due to SCI,; Presence of active spinally evoked responses over the lumbo-sacral spinal cord using scTS

Who cannot take part

  • Healing wounds/surgical sites along the spine, levels T9-L5,
  • Individuals unwilling or unable to wean from drug(s) that interact(s) with buspirone, such as: Monoamine oxidase inhibitors (MAOIs) - Selegiline (Emsam), Isocarboxazid (Marplan), Phenelzein (Nardil), and Tranylcypromine (Parnate)
  • Untreated active urinary tract infections,
  • Seizure disorders,
  • Cardiopulmonary disease unrelated to SCI,
  • Untreated clinically significant depression, psychiatric disorders, or ongoing drug abuse,
  • Individuals with abnormal blood panel results related to hepatic function, Individuals with abnormal estimated glomerular filtration rate (eGFR) and increase Creatinine Clearance (CrCl) levels above the normal range,
  • Untreated pressure sores,
  • Unhealed bone fractures,
  • Peripheral lower limb neuropathies unrelated to SCI,
  • Untreated anemia,
  • Ventilator dependency,
  • Female participants: Pregnant or planning to become pregnant during the time course of study, or nursing,
  • Anti-spasticity implantable pumps,
  • Colostomy bag, urostomy,

Where in United States

  • Frazier Rehabilitation and Neuroscience InstituteLouisville, United States

About the trial

What the trial wants to find out

The main goal of the project is to develop multiple noninvasive neuromodulatory strategies to facilitate full weight bearing stepping overground in people with paralysis. We will determine the effectiveness of combining noninvasive spinal cord stimulation and the administration of buspirone (a monoaminergic agonist) in facilitating locomotor activity in a gravity-neutral apparatus, during body weight supported stepping on a treadmill, when stepping overground, or during full weight bearing stepping overground in a rolling walker. Our objective is to identify the experimental variables that define the efficacy of these novel neuromodulatory techniques over a 5 year period in 15 participants with severe spinal cord injury who are at least one year post-injury.

The 3 groups in the trial

  • Complete Spinal Cord Injury - Gravity Neutral SteppingTreatment being tested

    Group 1 will begin with a 3-4-month preparation phase and up to 12 sessions in the gravity neutral device (GND) will occur. The training sessions in the GND will be used to obtain the optimal stimulation parameters. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. This will be done in the GND in the presence of stimulation. Afterwards, Intervention 2 will include the same training procedures with the addition of Buspirone or Placebo in a cross-over fashion halfway through this phase.

    Treatment: Buspirone, Non-invasive Spinal Cord Stimulation, Gravity Neutral Device, and Body Weight Supported Treadmill Training

  • Complete Spinal Cord Injury - Overground SteppingTreatment being tested

    Group 2 will begin with a 3-month preparation phase and up to 12 sessions of overground stepping. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours overground training, in the presence of stimulation and Buspirone/placebo. The second phase will include the same training procedures except for the removal of Buspirone/placebo administration. The third phase will include sessions twice per week of the overground with stimulation and one day per week using a rolling walker with stimulation. The last phase will include 2 sessions per week using the rolling walker in the presence of stimulation and Buspirone/placebo.

    Treatment: Buspirone, Non-invasive Spinal Cord Stimulation, Overground stepping, and Rolling Walker

  • Incomplete Spinal Cord Injury - Overground SteppingTreatment being tested

    Group 3 will begin with a 3-month preparation phase and up to 12 sessions stepping overground. Next, participants will enter Intervention Phase 1 where they will receive training sessions 3 days/week for approximately 2 hours. The overground session will use the rolling walker in the presence of stimulation. Afterwards, the second phase will include the same training procedures with the addition of Buspirone/placebo.

    Treatment: Buspirone, Non-invasive Spinal Cord Stimulation, Overground stepping, and Rolling Walker

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Transformation of Paraplegic Paralysis to Overground Stepping in Humans
Record updated
13 March 2026